Evidence map›Paper›PMID 36693694›Full record

ArticleBMJ open2023

Protocol for a MULTI-centre feasibility study to assess the use of

Hannah Warren, Thomas Wagner, Michael A Gorin, Steven Rowe, Beverley Fiona Holman, Deborah Pencharz, Soha El-Sheikh, Ravi Barod, Prasad Patki, Faiz Mumtaz and 21 more

Open access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. [European journal of nuclear medicine and molecular imaging · 2026
    Article
  3. Article
  4. Review
  5. Translational andrology and urology · 2024
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 12 institutions in 2 countries.

Hannah WarrenDivision of Surgery and Interventional Science, University College London, London, UK h.warren@ucl.ac.uk.ORCID 0000-0002-4106-2705
Thomas WagnerDepartment of Nuclear Medicine, Royal Free Hospital, London, UK.
Michael A GorinMilton and Carroll Petrie Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Steven RoweDepartment of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Beverley Fiona HolmanDepartment of Nuclear Medicine, Royal Free Hospital, London, UK.
Deborah PencharzDepartment of Nuclear Medicine, Royal Free Hospital, London, UK.
Soha El-SheikhSpecialist Centre for Kidney Cancer, Royal Free Hospital, London, UK.
Ravi BarodDivision of Surgery and Interventional Science, University College London, London, UK.
Prasad PatkiSpecialist Centre for Kidney Cancer, Royal Free Hospital, London, UK.
Faiz MumtazDivision of Surgery and Interventional Science, University College London, London, UK.
Axel BexDivision of Surgery and Interventional Science, University College London, London, UK.
Veeru KasivisvanathanDivision of Surgery and Interventional Science, University College London, London, UK.ORCID 0000-0002-0832-382X
Caroline M MooreDivision of Surgery and Interventional Science, University College London, London, UK.ORCID 0000-0003-0202-7912
Nicholas CampainDepartment of Urology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
Jon CartledgeDepartment of Urology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Andrew ScarsbrookDepartment of Radiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Fahim HassanDepartment of Nuclear Medicine, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Tim S O'BrienDepartment of Urology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Grant D StewartDepartment of Surgery, University of Cambridge, Cambridge, UK.ORCID 0000-0003-3188-9140
Iosif MendichovszkyDepartment of Radiology, University of Cambridge, Cambridge, UK.
Sabina DizdarevicDepartment of Nuclear Medicine, University Hospitals Sussex NHS Foundation Trust, Worthing, UK.
Ammar AlanbukiDepartment of Urology, University Hospitals Sussex NHS Foundation Trust, Worthing, UK.
William H WildgoosePatient Representative, London, UK.
Tze WahDepartment of Radiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Cecilia Vindrola-PadrosRapid Research, Evaluation and Appraisal Lab (RREAL), Department of Targeted Intervention, University College London, London, UK.ORCID 0000-0001-7859-1646
Elena PizzoDepartment of Applied Health Research, University College London, London, UK.
Hakim-Moulay DehbiInstitute of Clinical Trials and Methodology, University College London, London, UK.
Paula LorgellyDepartment of Applied Health Research, University College London, London, UK.
Kurinchi GurusamyDivision of Surgery and Interventional Science, University College London, London, UK.ORCID 0000-0002-0313-9134
Mark EmbertonDivision of Surgery and Interventional Science, University College London, London, UK.ORCID 0000-0003-4230-0338
Maxine G B TranDivision of Surgery and Interventional Science, University College London, London, UK.
The Royal Free Hospital · GBUniversity College London · GBLeeds Teaching Hospitals NHS Trust · GBGuy's and St Thomas' NHS Foundation Trust · GBUniversity College Hospital · GBUniversity of Cambridge · GBBrighton and Sussex Medical School · GBIcahn School of Medicine at Mount Sinai · USJohns Hopkins University · USMRC Clinical Trials Unit at UCL · GBRoyal Devon & Exeter NHS Foundation Trust · GBUniversity Hospitals Sussex NHS Foundation Trust · GB

Funding

Cancer Research UK C9685/A25177
6 · The paper itself

Abstract

introductionThe incidence of renal tumours is increasing and anatomic imaging cannot reliably distinguish benign tumours from renal cell carcinoma. Up to 30% of renal tumours are benign, with oncocytomas the most common type. Biopsy has not been routinely adopted in many centres due to concerns surrounding non-diagnostic rate, bleeding and tumour seeding. As a result, benign masses are often unnecessarily surgically resected. METHODS AND ANALYSIS: A feasibility prospective multicentre study of participants with indeterminate, clinical T1 renal tumours to undergo ETHICS AND DISSEMINATION: Ethical approval has been granted (UK HRA REC 20/YH/0279) protocol V.5.0 dated 21/6/2022. Study outputs will be presented and published nationally and internationally. TRIAL REGISTRATION NUMBER: ISRCTN12572202.

Indexed as

Kidney NeoplasmsTomography, Emission-Computed, Single-PhotonFeasibility StudiesHumansMulticenter Studies as TopicProspective StudiesRadiopharmaceuticalsTechnetium Tc 99m SestamibiTomography, X-Ray ComputedRadiopharmaceuticalsTechnetium Tc 99m SestamibiHEALTH ECONOMICSNuclear radiologyUrological tumours

Identifiers

PMID36693694
PMCPMC9884914
OpenAlexW4318027722

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.